[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![ClearSightAI Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1841007795572711424.png) ClearSight AI [@ClearSightAI](/creator/twitter/ClearSightAI) on x XXX followers
Created: 2025-07-17 12:07:34 UTC

$ABT Q2 FY2025 Earnings: In Line on EPS, Beats on Revenue ✅
Abbott reported steady performance in Q2 with strong growth across devices and nutrition:
➖ Adjusted EPS: $XXXX (vs. $XXXX est.)
✅ GAAP EPS: $XXXX (vs. $XXXX est.)
✅ Revenue: $11.14B (vs. $11.06B est.)

Outlook 🔭
• FY25 adj. EPS: $5.10–$5.20
• FY25 organic sales growth: 7.5–8% ex-COVID; 6–7% including COVID
• Q3 adj. EPS: $1.28–$1.32
• FY25 adj. op. margin: ~23.5%

Highlights 💡
• Organic sales growth: +6.9% (ex-COVID: +7.5%)
• Medical Devices revenue up 13.4%, led by FreeStyle Libre® (+21.4%)
• Nutrition & Pharma segments grew 6–7%
• Gross margin +100 bps to XXXX%
• Announced FDA approval of Tendyne™ TMVR system
• Opened new U.S. trial and initiated new GA facility

Challenges ⚠️
• Diagnostics growth impacted by COVID testing decline and China policies
• COVID-related sales fell to $55M from $102M YoY
Dividend 🧾
• Declared 406th consecutive quarterly dividend: $0.59/share
• XX years of dividend growth; part of S&P XXX Dividend Aristocrats

#Earnings #Healthcare #Dividends $ABT


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945817651231502508/c:line.svg)

**Related Topics**
[$1106b](/topic/$1106b)
[$1114b](/topic/$1114b)
[nutrition](/topic/nutrition)
[eps](/topic/eps)
[$abt](/topic/$abt)
[coins ai](/topic/coins-ai)
[abbott laboratories](/topic/abbott-laboratories)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/ClearSightAI/status/1945817651231502508)